home

FIXX.US | summary | financial summary | prediction chart | global stock news | news graph | compare | components | pairs | earnings

Key Financials FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
symbollastchange%chngnamemcapsectorwiki
FIXX Homology Medicines Inc 0.493B Healthcare

symbolprev.closerangecharttargetpercentperiodmonthsduerating
 B  FIXX 2.45 0,-0.102,-0.970,0.732,-0.102 1.88,1.62,1.51,1.45,1.55,2.13,1.85,2.06,1.94,2.08,2.23,2.34,2.32,2.55,2.94 2.97-3.49 31.90% 267,127,267 4.7 5Apr-28Dec 60.65%

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The impact shows the impact of the figure on the share price forecast. Sometimes the impact of an increasing beneficial figure may still be downwards when the increase was smaller than expected. The over figure shows if the actual result was higher or lower than the AI would forecast.

Income statement

. over affect Pred 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31
totalRevenue 1.153 -0.80 3.0 1M -3M 2M 2M 29M
grossProfit 0.493 4.240 1.0 1M 1M 2M 2M 29M
operatingIncome 0.369 6.914 -26.0 -38M -34M -31M -31M -1M
. netInterestIncome -1.01 -2.18 0.0 0M 0M 0M 0M 0M
incomeBeforeTax 1.114 -1.02 285.0 94M -34M -31M -30M -1M
taxProvision -0.30 -2.12 1.0 1M
netIncome -4.35 5.217 1.0 92M -34M -31M -30M -1M
otherOperatingExpenses 0 0.028 38.0 38M 32M 33M 30M
netIncomeApplicableToCommonShares -4.41 6.416 1.0 92M -34M -31M -30M -1M
reconciledDepreciation -0.24 23.61 0.0 0M 2M 2M 2M 2M

Balance sheet

. over affect Pred 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31
. itotalAssets -2.00 -1.86 42.0 311M 212M 231M 259M 235M
totalCurrentAssets 0 0.044 262.0 262M 192M 192M 218M 192M
. cashAndShortTermInvestments 0.018 -4.10 261.0 256M 156M 188M 213M 189M
. cash -0.13 -2.14 216.0 248M 108M 96M 116M 104M
otherAssets 0 0 0.0 0M 2M 1M 1M 1M
netWorkingCapital 0.100 4.757 267.0 242M 175M 173M 198M 174M
netInvestedCapital -0.29 7.933 198.0 266M 170M 199M 225M 201M
netDebt -0.06 2.936 -238.0 -224M -84M -82M -102M -90M

Cash Flow

. over affect Pred 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31
. totalCashFromOperatingActivities 0 0 -31.0 -31M -30M -25M -24M -30M
. . depreciationAndAmortization 0.277 0.260 0.0 0M 2M 2M 2M 2M
. . . changeToAccountReceivables 0 -0.13 nan
. . freeCashFlow 0.026 4.905 -31.0 -32M -31M -26M -25M -31M
. incomeTaxExpense. . -2.14 1.086 0.0 1M

``` ```